New drug targets Hard-to-Treat cancers with RAS mutations
NCT ID NCT07435038
First seen Mar 09, 2026 · Last updated Jun 16, 2026 · Updated 20 times
Summary
This early-stage study tests a new drug, BPI-572270, in adults with advanced solid tumors (lung, colorectal, pancreatic) that have specific RAS gene mutations. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 120 participants who have already tried standard treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.